Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 1
2(50.0%)
4Total
Phase 2(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT02215850Phase 1Completed

Safety Study of SLC-0111 in Subjects With Advanced Solid Tumours

Role: lead

NCT01098721Phase 2Completed

A Safety/Efficacy Study of a Non-steroid, Topical Cream Treatment of Psoriasis Over 12-weeks

Role: lead

NCT01098734Phase 2Completed

Non-steroid, Atopic Dermatitis Phase IIb 12-week Trial; Topical WBI-1001 Cream

Role: lead

NCT00837551Phase 1Completed

Phase IIa Study of WBI-1001 Cream for Atopic Dermatitis

Role: lead

NCT00830817Completed

Double-Blind Study of Topical WBI-1001 Cream on Patients With Psoriasis

Role: lead

All 5 trials loaded